Medical Cannabis in Oncology: Evidence, Uses, and Considerations

A balanced, evidence-based review of cannabinoids for symptom management in cancer patients

Key Points

• FDA-approved cannabinoids (dronabinol, nabilone) are available for CINV refractory to standard antiemetics — not as first-line therapy.
• Cannabis has NOT been proven to treat or cure cancer in humans; preclinical anti-tumor data does not translate to clinical practice.
• CBD is a strong CYP3A4 and CYP2C9 inhibitor — it can significantly raise levels of many chemotherapy drugs and increase toxicity.
• Always disclose cannabis use to your entire oncology team; many patients do not, and this creates serious drug interaction risk.
• Avoid smoking or combustion of cannabis; vaporization is safer for the lungs, but inhalation of any kind should be avoided when immunocompromised.
• Legal medical cannabis products vary widely in potency and composition — dispensary-obtained products are not standardized like pharmaceuticals.

Overview of Cannabinoids

Cannabis contains over 100 distinct cannabinoid compounds. The two most studied are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which act through the endocannabinoid system — a signaling network of receptors (primarily CB1 and CB2), endogenous ligands (endocannabinoids), and metabolic enzymes distributed throughout the body. CB1 receptors are concentrated in the central nervous system — particularly the brain regions controlling pain, mood, memory, and the vomiting reflex (area postrema). Activation by THC produces the characteristic psychoactive effects ("high"), as well as…

FDA-Approved Cannabinoid Medications

Several cannabinoid medications have received FDA approval for specific indications: Dronabinol (Marinol, Syndros) is synthetic THC and is Schedule III. It is FDA-approved for (1) CINV that is refractory to conventional antiemetic therapy, and (2) anorexia associated with AIDS-related weight loss. Capsules are available in 2.5, 5, and 10mg. The oral solution (Syndros) uses an alcohol-based formulation and interacts with disulfiram/metronidazole. Nabilone (Cesamet) is a synthetic THC analog (Schedule II) also FDA-approved for refractory CINV. It has a somewhat longer half-life than…

Evidence for Symptom Management

A nuanced interpretation of the evidence is essential when counseling cancer patients about cannabinoids: CINV: Dronabinol and nabilone are inferior to modern 5-HT3 antagonists plus NK1 antagonists as primary antiemetics. Their role is as adjunctive or rescue therapy for CINV refractory to optimal standard regimens. Most CINV guidelines (ASCO, NCCN, MASCC) include them as an option for breakthrough or refractory nausea but not as first-line. Cancer pain: A growing body of literature suggests cannabinoids may have opioid-sparing effects. A 2022 systematic review of 36 RCTs found modest but…

Drug Interactions with Chemotherapy

This section is critically important for oncology clinicians and patients. Both THC and CBD are substrates and inhibitors of cytochrome P450 (CYP) enzymes — the same enzyme system that metabolizes many chemotherapy agents. CBD is a potent inhibitor of CYP3A4 and CYP2C9. CYP3A4 is responsible for metabolizing approximately 50% of all medications, including many key oncology agents: docetaxel, paclitaxel, etoposide, irinotecan, vincristine, imatinib, erlotinib, ibrutinib, and many others. Inhibiting CYP3A4 with CBD can significantly raise plasma concentrations of these drugs — potentially…

Practical Guidance for Patients

For patients in states where medical cannabis is legal and who wish to explore it as supportive care, the following practical guidance applies: Start low, go slow: Begin with a low-THC, CBD-dominant product. Starting doses of CBD 5–10mg once or twice daily allow assessment of tolerability. Add THC cautiously if needed, starting at 1–2.5mg THC. Timing matters: For sleep, THC-containing products are best taken 1–2 hours before bed. For daytime nausea management, lower-THC or balanced THC:CBD products minimize psychoactive effects. Avoid combustion: Smoking cannabis delivers carcinogens and…

Professional Society Positions and Special Populations

Professional oncology societies have adopted cautious but evolving positions: ASCO (2018 position statement): There is insufficient evidence to recommend medical cannabis for most cancer-related indications outside of clinical trials. Dronabinol and nabilone are appropriate options for refractory CINV. ASCO encourages further research. NCI: Lists cannabinoids in its integrative oncology resources, acknowledging the evolving evidence base for pain, CINV, and appetite stimulation. Emphasizes the absence of proven anti-tumor efficacy in humans. NCCN: Includes cannabinoids in antiemesis and…